1. NOV. 2021

boehringer-ingelheim.com › human-health › mental-disorders › schizophrenia

Introducing CIAS (Cognitive Impairment Associated with Schizophrenia) . Schizophrenia affects 1 in 100, yet the condition can be misunderstood due to some symptoms being overlooked, such as cognitive impairment. Read…

11. SEPT. 2020

boehringer-ingelheim.com › press-release › phase-ii-results-cognitive

Finding solutions for cognitive impairment is a key area of Boehringer Ingelheim CNS research. Notes to editors. Study 1346.9 was a Phase II, randomized, double-blind, placebo-controlled, parallel group trial across…

6. DEZ. 2019

boehringer-ingelheim.com › central-nervous-system › prevention-schizophrenia

Boehringer Ingelheim Can schizophrenia be prevented? That’s what investigators are hoping to find out, according to scientists attending the American College of Neuropsychopharmacology (ACNP) in Orlando, Florida.

14. SEPT. 2020

fiercebiotech.com › biotech › boehringer-s-schizophrenia-med-boosts-cognition

Boehringer Ingelheim’s schizophrenia hopeful hit the mark in a phase 2 study, helping patients overcome cognitive impairment that can affect everyday tasks, such as remembering important dates or s

24. MAI 2021

boehringer-ingelheim.com › press-release › btd-glyt1-schizophrenia

Ingelheim, 25 May 2021 – Boehringer Ingelheim today announced that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) for BI 425809 for the treatment of…

24. MAI 2021

prnewswire.com › news-releases › boehringer-ingelheims-investigational

Boehringer Ingelheim's Investigational Treatment for Cognitive Impairment Associated with Schizophrenia Receives FDA Breakthrough Therapy Designation. BI 425809, A Novel Glycine transporter-1 ...

11. SEPT. 2020

boehringer-ingelheim.com › press-release › partnership-clicktherapeutics

Boehringer Ingelheim and Click Therapeutics Enter into Collaboration to Develop and Commercialize CT-155, a Novel Prescription Digital Therapeutic to Aid in the Treatment of Schizophrenia. Ingelheim, Germany and New York,…

clicktherapeutics.com › press › boehringer-click-to-develop-and-commercialize

Further it has the potential to be prescribed together with Boehringer Ingelheim’s schizophrenia pipeline compounds possibly enhancing the benefit of pharmacotherapy for patients,” added Cornelia Dorner-Ciossek, Ph.D., Director CNS Diseases…

clinicaltrials.gov › ct2 › show › NCT05438160

Brief Summary: CT-155 is a novel prescription digital therapeutic (PDT) being developed by Click Therapeutics, Inc. (Click) and Boehringer Ingelheim (BI) using an interactive, software-based intervention to treat schizophrenia. Condition…

7. SEPT. 2022

pro.boehringer-ingelheim.com › events › cns-congresses › ecnp-focus-on-schizophrenia

Our approach to Cognitive Impairment Associated with Schizophrenia (CIAS) Hear about the impact of CIAS and why Boehringer Ingelheim is focusing on this to push the boundaries of mental health…

21. MAI 2021

boehringer-ingelheim.com › us › press-release › boehringer-ingelheims

RIDGEFIELD, CT, May 24, 2021 – Boehringer Ingelheim today announced that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) for BI 425809 for the treatment…

annualreport.boehringer-ingelheim.com › 2021 › magazine › mental-health-diseases

Boehringer Ingelheim is collaborating on CT-155, which will address key unmet needs in the treatment of schizophrenia. As an adjunct to pharmacotherapy, CT-155 is intended to offer patients an engaging…

fiercebiotech.com › medtech › boehringer-ingelheim-test-click-therapeutics

A yearslong collaboration between Click Therapeutics and drugmaker Boehringer Ingelheim exploring the potential of digital apps in schizophrenia therapy will now be put to the test in the clinic.